---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-25-000115"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:22:10.467366+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO

## Summary
- Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.
- Amy C. Peterson, M.D., concluded service as EVP Product Development and CMO on same date.
- Dr. Peterson eligible for severance under Exelixis's Change in Control and Severance Benefit Plan.
- No other officer changes disclosed; Dr. Aftab's compensation terms unchanged from prior proxy filing.

## SEC filing metadata
- accession: 0000939767-25-000115
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976725000115/0000939767-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976725000115/exel-20250829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-25-000115
- JSON: https://secwatch.observer/filing/0000939767-25-000115.json
- Plain text: https://secwatch.observer/filing/0000939767-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.